Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

Stopped The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges

Conditions

• Osteosarcoma
• Osteosarcoma in Children
• Osteosarcoma in Adolescents and Young Adults

Interventions

• DRUG: Cabozantinib
• OTHER: Best Supportive Care (BSC)
• OTHER: Best Supportive Care (BSC)

Sponsor

Ipsen